Compare QXO Inc. Common Stock (QXO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QXO Inc. Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? QXO Inc. Common Stock trades at $10.33 (market cap $11.43B), while Recursion Pharmaceuticals Inc trades at $3.67 (market cap $2.08B). The key difference: QXO Inc. Common Stock is far larger — about 5.5× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, QXO Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold QXO Inc. Common Stock for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| QXO | RXRX | |
|---|---|---|
Market Cap | $11.43B | $2.08B |
Volume | 21,645,941 | 19,700,033 |
Sector | Industrials | Health |
52-Week High | $27.07 | $6.79 |
52-Week Low | $10.33 | $2.84 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $16.75B | $1.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.
The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported revenue of $74.26M in 2025 but posted a significant net loss of -$644.76M, reflecting negative profit margins. Recent news highlights strategic AI partnerships and pipeline expansion, though the stock faces high short interest and ongoing operational losses.
Outlook remains speculative with 40% analyst buy ratings but substantial financial losses. Key opportunities include AI-driven drug discovery partnerships, while risks involve cash burn, competitive pressures, and delayed profitability. The stock's valuation at 36.1x sales appears stretched given current financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About QXO Inc. Common Stock
QXO, Inc. is a distributor of roofing, insulation, waterproofing, and other building materials, serving contractors and builders across US and Canada through its network of branch locations.
Read more on QXO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
